Statement: the primary trial only recorded one type of acute adverse event.
Primary_evidence: Adverse Events 1:   Total: 23/78 (29.49%)   Febrile neutropenia * 4/78 (5.13%)   Neutropenia * 1/78 (1.28%)   Thrombocytopenia * 0/78 (0.00%)   Acute coronary syndrome * 1/78 (1.28%)   Cardiac failure congestive * 1/78 (1.28%)   Myocardial infarction * 1/78 (1.28%)   Cardiomyopathy * 0/78 (0.00%)   Abdominal pain * 1/78 (1.28%)   Diarrhoea * 1/78 (1.28%)   Upper gastrointestinal haemorrhage * 1/78 (1.28%) Adverse Events 2:   Total: 24/75 (32.00%)   Febrile neutropenia * 8/75 (10.67%)   Neutropenia * 3/75 (4.00%)   Thrombocytopenia * 2/75 (2.67%)   Acute coronary syndrome * 0/75 (0.00%)   Cardiac failure congestive * 2/75 (2.67%)   Myocardial infarction * 0/75 (0.00%)   Cardiomyopathy * 1/75 (1.33%)   Abdominal pain * 0/75 (0.00%)   Diarrhoea * 1/75 (1.33%)   Upper gastrointestinal haemorrhage * 0/75 (0.00%)